Ian Walters
Overview
Explore the profile of Ian Walters including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
1085
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jneid B, Bochnakian A, Hoffmann C, Delisle F, Djacoto E, Sirven P, et al.
Sci Immunol
. 2023 Jan;
8(79):eabn6612.
PMID: 36638189
T cells that recognize tumor antigens are crucial for mounting antitumor immune responses. Induction of antitumor T cells in immunogenic tumors depends on STING, the intracellular innate immune receptor for...
2.
Creemers J, Pawlitzky I, Grosios K, Gileadi U, Middleton M, Gerritsen W, et al.
BMJ Open
. 2021 Dec;
11(11):e050725.
PMID: 34848513
Introduction: The undiminished need for more effective cancer treatments stimulates the development of novel cancer immunotherapy candidates. The archetypical cancer immunotherapy would induce robust, targeted and long-lasting immune responses while...
3.
Bloom A, Bender L, Tiwary S, Pasquet L, Clark K, Jiang T, et al.
Oncoimmunology
. 2019 Oct;
8(10):e1625687.
PMID: 31646070
The benefits of anti-cancer agents extend beyond direct tumor killing. One aspect of cell death is the potential to release antigens that initiate adaptive immune responses. Here, a diffusion enhanced...
4.
Jones R, Ratain M, ODwyer P, Siu L, Jassem J, Medioni J, et al.
Eur J Cancer
. 2019 Sep;
120:132-139.
PMID: 31522033
Background: Brivanib is a selective inhibitor of vascular endothelial growth factor and fibroblast growth factor (FGF) signalling. We performed a phase II randomised discontinuation trial of brivanib in 7 tumour...
5.
Lencioni R, Montal R, Torres F, Park J, Decaens T, Raoul J, et al.
J Hepatol
. 2017 Jan;
66(6):1166-1172.
PMID: 28131794
Background & Aims: The Modified Response Evaluation Criteria in Solid Tumors (mRECIST) was developed to overcome the limitations of standard RECIST criteria in response assessment of hepatocellular carcinoma (HCC). We...
6.
Nakamura I, Zakharia K, Banini B, Mikhail D, Kim T, Yang J, et al.
PLoS One
. 2015 Nov;
10(11):e0142355.
PMID: 26528545
No abstract available.
7.
Raoul J, Park J, Kang Y, Finn R, Kim J, Yeo W, et al.
Liver Cancer
. 2015 Aug;
3(3-4):439-50.
PMID: 26280005
Background And Aims: Assessing treatment responses in hepatocellular carcinoma (HCC) is challenging, and alternative radiologic methods of measuring treatment response are required. Modified Response Evaluation Criteria in Solid Tumors (mRECIST)...
8.
Schiff D, Kesari S, de Groot J, Mikkelsen T, Drappatz J, Coyle T, et al.
Invest New Drugs
. 2014 Nov;
33(1):247-53.
PMID: 25388940
VEGF signaling through VEGFR-2 is the major factor in glioblastoma angiogenesis. CT-322, a pegylated protein engineered from the 10th type III human fibronectin domain, binds the VEGFR-2 extracellular domain with...
9.
Nakamura I, Zakharia K, Banini B, Mikhail D, Kim T, Yang J, et al.
PLoS One
. 2014 Apr;
9(4):e92273.
PMID: 24710173
Background And Aims: Brivanib is a selective inhibitor of vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR) tyrosine kinases, which are both involved in mechanisms of...
10.
Ringash J, Au H, Siu L, Shapiro J, Jonker D, Zalcberg J, et al.
Cancer
. 2013 Oct;
120(2):181-9.
PMID: 24127364
Background: The CO.20 trial randomized patients with K-RAS wild-type, chemotherapy-refractory, metastatic colorectal cancer to receive cetuximab (CET) plus brivanib alaninate (BRIV) or CET plus placebo (CET/placebo). Methods: Quality of life...